Barchart on Facebook
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Allogene Therapeutics Inc (ALLO)

Allogene Therapeutics Inc (ALLO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 5,056,300
  • Shares Outstanding, K 139,292
  • Annual Sales, $ 0 K
  • Annual Income, $ -184,590 K
  • 60-Month Beta 1.60
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 3.81
Trade ALLO with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 15 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/20
See More
  • Average Estimate -0.55
  • Number of Estimates 9
  • High Estimate -0.47
  • Low Estimate -0.62
  • Prior Year -0.50
  • Growth Rate Est. (year over year) -10.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
33.77 +7.49%
on 09/24/20
44.92 -19.19%
on 10/14/20
+1.08 (+3.07%)
since 09/23/20
3-Month
31.61 +14.84%
on 09/04/20
44.92 -19.19%
on 10/14/20
-3.15 (-7.98%)
since 07/23/20
52-Week
17.43 +108.26%
on 03/18/20
55.00 -34.00%
on 05/26/20
+8.41 (+30.15%)
since 10/23/19

Most Recent Stories

More News
Allogene Therapeutics and MD Anderson Announce Strategic Collaboration to Accelerate Advancement of Allogeneic CAR T Therapy (AlloCAR T(TM))

-- Clinical and Translational Research Collaboration Will Evaluate Multiple AlloCAR T Candidates Across the Allogene Portfolio Targeting Multiple Tumor Types

ALLO : 36.30 (+2.72%)
Allogene Therapeutics Announces October 2020 Virtual Investor Conference Participation

Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T(TM)) therapies for cancer, today announced that management plans...

ALLO : 36.30 (+2.72%)
Allogene Therapeutics (ALLO) Down 9.9% Since Last Earnings Report: Can It Rebound?

Allogene Therapeutics (ALLO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

ALLO : 36.30 (+2.72%)
Allogene Therapeutics Announces September 2020 Virtual Investor Conference Participation

Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T(TM)) therapies for cancer, today announced that management plans...

MS : 51.87 (+0.19%)
ALLO : 36.30 (+2.72%)
Allogene's (ALLO) Q2 Loss Widens Y/Y, Pipeline Progresses

Allogene (ALLO) reports no revenues for the second quarter of 2020.

EBS : 96.11 (-1.58%)
HZNP : 77.44 (+1.81%)
UMRX : 2.35 (+0.43%)
ALLO : 36.30 (+2.72%)
Allogene Therapeutics: 2Q Earnings Snapshot

SOUTH SAN FRANCISCO, Calif. (AP) _ Allogene Therapeutics Inc. (ALLO) on Wednesday reported a loss of $61 million in its second quarter.

ALLO : 36.30 (+2.72%)
Allogene Therapeutics Reports Second Quarter 2020 Financial Results

-- In the ALPHA Trial, Higher Dose ALLO-647 was Associated with Deeper Lymphodepletion, Delayed Host T Cell Recovery and a Higher Complete Response Rate

ALLO : 36.30 (+2.72%)
Is Allogene Therapeutics (ALLO) Stock Outpacing Its Medical Peers This Year?

Is (ALLO) Outperforming Other Medical Stocks This Year?

ALLO : 36.30 (+2.72%)
Allogene Therapeutics Presents Preclinical Findings Supporting an Allogeneic DLL3 CAR for Small Cell Lung Cancer and Development of an Inducible TurboCAR(TM) at the American Association for Cancer Research (AACR) Virtual 2020 Meeting

Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T(TM)) therapies for cancer, today announced that preclinical...

ALLO : 36.30 (+2.72%)
Allogene Therapeutics Announces Publication Highlighting Potential for ALLO-819 In Acute Myeloid Leukemia

-- FLT3-Directed AlloCAR T(TM) Therapy Demonstrated Potent Anti-Leukemic Activity in Pre-Clinical Models Without Evidence of Off-Target Activity

ALLO : 36.30 (+2.72%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakest short term outlook on maintaining the current direction.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Allogene Therapeutics, Inc. is a biotechnology company. It develops allogeneic chimeric antigen receptor T-cell therapy for the treatment of blood cancers and solid tumors. The company's product pipeline consists of UCART19, ALLO-501, ALLO-715, ALLO-819, CD70, DLL3 and ALLO-647 which are in clinical...

See More

Key Turning Points

2nd Resistance Point 37.61
1st Resistance Point 36.95
Last Price 36.30
1st Support Level 35.10
2nd Support Level 33.91

See More

52-Week High 55.00
Fibonacci 61.8% 40.65
Last Price 36.30
Fibonacci 50% 36.22
Fibonacci 38.2% 31.78
52-Week Low 17.43

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar